AstraZeneca Plc (NASDAQ:AZN) is reportedly reconsidering its planned $578.4 million (450 million pounds) investment in a new vaccine-manufacturing site, a departure from CEO Pascal Soriot‘s ...
AstraZeneca is backing up its considerable ... Chief executive Pascal Soriot said the plant will help AZ achieve its ambition to position ADCs as a replacement for traditional chemotherapies ...
CAMBRIDGE, England, November 12, 2024--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and ...